ImportancePredetermined Change Control Plans (PCCPs) are a recent regulatory innovation by the U.S. Food and Drug Administration (FDA) introduced to enable dynamic oversight of artificial intelligence and machine learning (AI/ML)-enabled medical devices. ObjectiveTo characterize FDA program of PCCPs among AI/ML-enabled medical devices, including device characteristics, preapproval testing, planned modifications, and post-clearance update mechanisms. DesignThis cross-sectional study reviewed FDA-cleared or approved AI/ML-enabled medical devices with authorized PCCPs. SettingAI/ML-enabled devices approved or cleared prior to May 30, 2025 were identified from an FDA-maintained public list and their characteristics extracted from FDA approval databases. ParticipantsN/A Main Outcome(s) and Measure(s)Primary outcomes included (1) prevalence and characteristics of devices with authorized PCCPs, (2) types of FDA-authorized modifications, (3) presence and nature of preapproval testing, such as study design and subgroup testing, and (4) postmarket device update mechanisms and transparency. ResultsAmong 26 identified AI/ML-enabled medical devices with authorized PCCPs, 92% were cleared via the 510(k) pathway, and all were classified as moderate risk. Devices were primarily intended for use in diagnosis or clinical assessment, and six had consumer-facing components. Authorized modifications spanned the product lifecycle, most commonly allowing model retraining (69% of devices), logic updates (42% of devices), and expansion of input sources (35% of devices). Preapproval testing was limited with seven devices prospectively evaluated and thirteen undergoing human factors testing. Subgroup analyses were reported for eleven devices and none included patient outcomes data. No postmarket studies or recalls were identified. User manuals could be identified online for 54% of devices, though many lacked performance details or mentioned PCCPs. Conclusions and RelevanceFDA authorization of PCCPs grants manufacturers substantial flexibility to modify AI/ML-enabled devices postmarket, while preapproval testing and postmarket transparency are limited. These findings highlight the need for strengthened oversight mechanisms to ensure ongoing safety and effectiveness of rapidly evolving AI/ML-enabled technologies in clinical care.

BackgroundGadolinium-based Contrast Agents (GBCAs) are used in brain MRI exams to improve the visualization of pathology and improve the delineation of lesions. Higher doses of GBCAs can improve lesion sensitivity but involve substantial deviation from standard-of-care procedures and may have safety implications, particularly in the light of recent findings on gadolinium retention and deposition. PurposeTo evaluate the clinical performance of an FDA cleared deep-learning (DL) based contrast boosting algorithm in routine clinical brain MRI exams. MethodsA multi-center retrospective database of contrast-enhanced brain MRI images (obtained from April 2017 to December 2023) was used to evaluate a DL-based contrast boosting algorithm. Pre-contrast and standard post-contrast (SC) images were processed with the algorithm to obtain contrast boosted (CB) images. Quantitative performance of CB images in comparison to SC images was compared using contrast-to-noise ratio (CNR), lesion-to-brain ratio (LBR) and contrast enhancement percentage (CEP). Three board-certified radiologists reviewed CB and SC images side-by-side for qualitative evaluation and rated them on a 4-point Likert scale for lesion contrast enhancement, border delineation, internal morphology, overall image quality, presence of artefacts, and changes in vessel conspicuity. The presence, cause, and severity of any false lesions was recorded. CB results were compared to SC using Wilcoxon signed rank test for statistical significance. ResultsBrain MRI images from 110 patients (47 {+/-} 22 years; 52 Females, 47 Males, 11 N/A) were evaluated. CB images had superior quantitative performance than SC images in terms of CNR (+634%), LBR (+70%) and CEP (+150%). In the qualitative assessment CB images showed better lesion visualization (3.73 vs 3.16) and had better image quality (3.55 vs 3.07). Readers were able to rule out all false lesions on CB by using SC for comparison. ConclusionsDeep learning based contrast boosting improves lesion visualization and image quality without increasing contrast dosage. Key ResultsO_LIIn a retrospective study of 110 patients, deep-learning based contrast boosted (CB) images showed better lesion visualization than standard post-contrast (SC) brain MRI images (3.73 vs 3.16; mean reader scores [4-point Likert scale]) C_LIO_LICB images had better overall image quality than SC images (3.55 vs 3.07) C_LIO_LIContrast-to-noise ratio, Lesion-to-brain Ratio and Contrast Enhancement Percentage for CB images were significantly higher than SC images (+729%, +88% and +165%; p < 0.001) C_LI Summary StatementDeep-learning based contrast boosting achieves better lesion visualization and overall image quality and provides more contrast information, without increasing the contrast dosage in contrast-enhanced brain MR protocols.